Combination Nivolumab, CD137 Agonism, and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma.

MacLean S Hall John E Mullinax Cheryl A Cox Amy M Hall Matthew S Beatty Jamie Blauvelt Patrick Innamarato Luz E Nagle Holly Branthoover Doris Wiener Benjamin I Schachner Alberto J Martinez Allison D Richards Carolyn J Rich Marjorie Colón Colón Michael J Schell Jamie K Teer Nikhil I Khushalani Jeffrey S Weber James J Mule Vernon K Sondak Shari A Pilon-Thomas Amod A Sarnaik

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)

Combination therapy with TIL and nivolumab was safe and feasible for metastatic melanoma patients and provides important insights for future therapeutic developments in ACT with TIL.

Keyphrases

cell therapy
combination therapy
end stage renal disease
stem cells
ejection fraction
mesenchymal stem cells
newly diagnosed
chronic kidney disease
peritoneal dialysis
peripheral blood
patient reported outcomes
current status